التفاصيل البيبلوغرافية
| العنوان: |
Repeat serological testing for anti‐citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis. |
| المؤلفون: |
Reid, Alistair B., Wiese, Michael, McWilliams, Leah, Metcalf, Rob, Hall, Cindy, Lee, Anita, Hill, Catherine, Wechalekar, Mihir, Cleland, Les, Proudman, Susanna M. |
| المصدر: |
Internal Medicine Journal; Jul2020, Vol. 50 Issue 7, p818-822, 5p, 3 Charts |
| مصطلحات موضوعية: |
RHEUMATOID arthritis treatment, ANTIRHEUMATIC agents, AUTOANTIBODIES, CONFIDENCE intervals, FISHER exact test, IMMUNOENZYME technique, SERODIAGNOSIS, SEROCONVERSION, DATA analysis software, DESCRIPTIVE statistics, MANN Whitney U Test |
| مستخلص: |
Aim: To Investigate the prevalence of seroconversion to ACPA after commencement of triple disease‐modifying anti‐rheumatic drug (DMARD) treat‐to‐target therapy. Background: Anti‐citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) define 'seropositive' rheumatoid arthritis (RA). Both predict unfavourable disease course, development of extra‐articular features and treatment outcomes. We investigated the prevalence of seroconversion to ACPA after commencement of triple disease‐modifying anti‐rheumatic drug (DMARD) treat‐to‐target therapy. Methods: DMARD‐naïve patients with RA according to the 1987 American College of Rheumatology criteria and disease duration of <96 weeks were enrolled. RF and ACPA levels were recorded at baseline and sequentially during triple DMARD therapy. Results: A total of 368 patients were followed for a median of 272 weeks. Of 154 patients seronegative for ACPA at recruitment, 10 (6.5%) seroconverted at some point. Nine of these were positive for RF at baseline and baseline RF titre was predictive of seroconversion. Four (2.6%) patients remained seropositive. No patients seroconverted from negative to positive for both RF and ACPA. Median time to seroconversion for ACPA was 29 months. Conclusion: Persistent seroconversion of ACPA from negative to positive after diagnosis in patients with RA is uncommon. ACPA and RF double negative patients are highly unlikely to ever develop ACPA positivity with a risk <1%. It is therefore unlikely to be helpful or cost effective to perform serial ACPA measurements in patients with seronegative RA after commencement of a treat‐to‐target strategy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Internal Medicine Journal is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
